Product Details
Cresemba
Isavuconazole100 mg
Capsule
DIN/PIN/NPN
02483971
Manufacturer
Avir Pharma Inc.
Formulary Listing Date
2020-03-04
Unit Price
78.8300
Amount MOH Pays
78.8300
Coverage Status
Exceptional Access Program Product
ODB Formulary Therapeutic Classification
Therapeutic Note
NO
ATC Code
J02AC05
Interchangeable Products
NOLU Clinical Criteria
NOEAP Criteria
Therapeutic Class | Reimbursement Criteria |
---|---|
Anti-Infectives | Isavuconazole
NOTE: Prescribers must submit the laboratory results to confirm the patient's infection and include drugs and drug regimens that have been used for the patient's condition, including the response to prior therapies and other relevant clinical information. Please also confirm that the patient does not meet the exclusion criteria. For the treatment of invasive aspergillosis in patients meeting the following criteria:
Exclusion criteria: Approval Duration: 3 months Renewals will be considered on a case-by-case basis. For the treatment of invasive mucormycosis in patients meeting the following criteria:
Exclusion criteria: Approval Duration: 3 months Renewals will be considered on a case-by-case basis Recommended dose: Oral therapy should be considered as a preferred option when clinically appropriate. A loading dose is not required when switching from intravenous to oral treatment or vice versa. EAP Drug Request Form: |
Anti-Infectives – Telephone Request Service (TRS) Drugs | Isavuconazole
NOTE: Prescribers must submit the laboratory results to confirm the patient's infection and include drugs and drug regimens that have been used for the patient's condition, including the response to prior therapies and other relevant clinical information. Please also confirm that the patient does not meet the exclusion criteria. For the treatment of invasive aspergillosis in patients meeting the following criteria:
Exclusion criteria: Approval Duration: 3 months Renewals will be considered on a case-by-case basis. For the treatment of invasive mucormycosis in patients meeting the following criteria:
Exclusion criteria: Approval Duration: 3 months Renewals will be considered on a case-by-case basis Recommended dose: Oral therapy should be considered as a preferred option when clinically appropriate. A loading dose is not required when switching from intravenous to oral treatment or vice versa. |